Laurie D. Stelzer Net Worth

The estimated Net Worth of Laurie Stelzer is at least $8.8 Milión dollars as of 2 June 2023. Ms Stelzer owns over 4,647 units of Arena Pharmaceuticals Inc stock worth over $8,000,700 and over the last 9 years she sold ARNA stock worth over $172,218. In addition, she makes $630,765 as Exec. VP & CFO at Arena Pharmaceuticals Inc.

Ms Stelzer ARNA stock SEC Form 4 insiders trading

Ms has made over 17 trades of the Arena Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 4,647 units of ARNA stock worth $172,218 on 2 June 2023.

The largest trade she's ever made was exercising 23,120 units of Arena Pharmaceuticals Inc stock on 3 February 2018 worth over $2,311,769. On average, Ms trades about 5,341 units every 73 days since 2015. As of 2 June 2023 she still owns at least 80,015 units of Arena Pharmaceuticals Inc stock.

You can see the complete history of Ms Stelzer stock trades at the bottom of the page.

Ms. Laurie D. Stelzer biography

Laurie D. Stelzer is the Exec. VP & CFO at Arena Pharmaceuticals Inc.

What is the salary of Ms Stelzer?

As the Exec. VP & CFO of Arena Pharmaceuticals Inc, the total compensation of Ms Stelzer at Arena Pharmaceuticals Inc is $630,765. There are 6 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of $8,931,400.

How old is Ms Stelzer?

Ms Stelzer is 53, she's been the Exec. VP & CFO of Arena Pharmaceuticals Inc since . There are 7 older and 5 younger executives at Arena Pharmaceuticals Inc. The oldest executive at Arena Pharmaceuticals Inc is Garry Neil, 67, who is the Independent Director.

What's Ms Stelzer's mailing address?

Laurie's mailing address filed with the SEC is C/O PMV PHARMACEUTICALS, INC., 1 RESEARCH WAY, PRINCETON, NJ, 08540.

Insiders trading at Arena Pharmaceuticals Inc

Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over $9,243,184 worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth $252,505 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Manmeet Singh Soni a Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of $3,133,387. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth $48,190.

What does Arena Pharmaceuticals Inc do?

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas

Complete history of Ms Stelzer stock trades at Aeglea BioTherapeutics Inc, Arena Pharmaceuticals Inc, Halozyme Therapeutics, Mirati Therapeutics Inc, Surface Oncology Inc a Pmv Pharmaceuticals Inc

Arena Pharmaceuticals Inc executives and stock owners

Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Amit Munshi,
  Director, President and Chief Executive Officer
• Vincent Aurentz,
  Executive Vice President and Chief Business Officer
• Robert Lisicki,
  Executive Vice President and Chief Commercial Officer
• Amit D. Munshi M.B.A.,
  Pres, CEO & Director
• Vincent E. Aurentz,
  Exec. VP & Chief Bus. Officer
• Dr. Christopher H. Cabell FACC, M.D., MHS,
  Advisor
• Laurie D. Stelzer,
  Exec. VP & CFO
• Joan Schmidt,
  Exec. VP, Gen. Counsel & Sec.
• Tina Nova,
  Independent Chairman of the Board
• Jennifer Jarrett,
  Independent Director
• Randall Woods,
  Independent Director
• Jayson Dallas,
  Independent Director
• Manmeet Soni,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Oliver Fetzer,
  Independent Director
• Garry Neil,
  Independent Director
• Katharine Knobil,
  Director
• Joan Schmidt,
  Executive Vice President, General Counsel, Secretary
• Laurie Stelzer,
  Chief Financial Officer, Executive Vice President
• Patrick Malloy,
  VP of Investor Relations & Corp. Communications
• Megan E. Knight,
  Director of Investor Relations
• Dr. Lamine Mbow Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. Douglas A. Bakan Ph.D.,
  Exec. VP of Technical Operations
• Harry F Jr Hixson,
  Director
• Maurice James Mezzino,
  SVP, Corporate Development
• Phillip M Schneider,
  Director
• Preston Klassen,
  EVP and CMO
• Steven W Spector,
  EVP, General Counsel & Sec
• Scott H Bice,
  Director
• Kevin Robert Lind,
  Executive VP and CFO
• Christine Anna White,
  Director
• Donald D Belcher,
  Director
• Nawal Ouzren,
  Director
• Frederick Frank,
  
• Mark N Lampert,
  Director
• Robert Hoffman,
  SVP, Finance and CFO
• Partners L P/Ilbiotechnolog...,
  
• James Laforce,
  Director
• Jennifer Kathleen Bielasz,
  VP, Accounting & Controller
• K A Ajit Simh,
  VP, Quality Systems
• Jack Lief,
  Chairman, President and CEO
• Craig Michael Audet,
  SVP, Opn & Head Glob Reg Afrs
• Duke K Bristow,
  Director
• Robert L Toms,
  Director
• Paul W Maffuid,
  VP, Pharmaceutical Development
• Joyce H Williams,
  VP, Drug Development
• Partners L P/Ilbvf Inc/Ilbi...,
  
• Nigel R A Beeley,
  VP, Chief Chemical Officer
• Joseph F Mooney,
  Chief Financial Officer
• Derek T Chalmers,
  Vice President, Research
• Louis J Scotti,
  VP, Marketing and Bus Dev
• Dominic P Behan,
  EVP & Chief Scientific Officer
• James Edeerfield Capital Lp...,
  
• Louis J Jr Lavigne,
  Director
• William R Jr Shanahan,
  SVP & Chief Medical Officer
• Christopher Cabell,
  EVP, Head of R&D, and CMO
• Steven J Schoch,
  Director
• Douglas J. Manion,
  EVP Research & Development